Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00199160 ↗

Phase 2 Completed 60 enrolled Jules Bordet Institute

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II trial evaluating the efficacy and the biological activity of BAY 43-9006 in patients with recurrent and/or metastatic head and neck cancer.

Timeline

Start: 2005-04
Primary completion: 2010-06
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	—	—

Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Summary

Timeline

Drugs

Indications